195 related articles for article (PubMed ID: 9609411)
1. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.
Baudo F; Caimi TM; de Cataldo F; Ravizza A; Arlati S; Casella G; Carugo D; Palareti G; Legnani C; Ridolfi L; Rossi R; D'Angelo A; Crippa L; Giudici D; Gallioli G; Wolfler A; Calori G
Intensive Care Med; 1998 Apr; 24(4):336-42. PubMed ID: 9609411
[TBL] [Abstract][Full Text] [Related]
2. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
Warren BL; Eid A; Singer P; Pillay SS; Carl P; Novak I; Chalupa P; Atherstone A; Pénzes I; Kübler A; Knaub S; Keinecke HO; Heinrichs H; Schindel F; Juers M; Bone RC; Opal SM;
JAMA; 2001 Oct; 286(15):1869-78. PubMed ID: 11597289
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.
Fourrier F; Chopin C; Huart JJ; Runge I; Caron C; Goudemand J
Chest; 1993 Sep; 104(3):882-8. PubMed ID: 8365305
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin III in patients admitted to intensive care units: a multicenter observational study.
Messori A; Vacca F; Vaiani M; Trippoli S;
Crit Care; 2002 Oct; 6(5):447-51. PubMed ID: 12398786
[TBL] [Abstract][Full Text] [Related]
6. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.
Wiedermann CJ; Hoffmann JN; Juers M; Ostermann H; Kienast J; Briegel J; Strauss R; Keinecke HO; Warren BL; Opal SM;
Crit Care Med; 2006 Feb; 34(2):285-92. PubMed ID: 16424704
[TBL] [Abstract][Full Text] [Related]
7. Antithrombin III in Sepsis. New evidences and open questions.
Ostermann H
Minerva Anestesiol; 2002 May; 68(5):445-8. PubMed ID: 12029261
[TBL] [Abstract][Full Text] [Related]
8. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
[TBL] [Abstract][Full Text] [Related]
9. Impact of withdrawing antithrombin III administration from management of septic patients with or without disseminated intravascular coagulation.
Kawano S; Uchino S; Endo A; Saito K; Iwai K; Kase Y; Takinami M
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):795-800. PubMed ID: 24806318
[TBL] [Abstract][Full Text] [Related]
10. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation.
Haire WD; Ruby EI; Stephens LC; Reed E; Tarantolo SR; Pavletic ZS; Bierman PJ; Bishop M; Kessinger A; Vose J; Armitage JO
Biol Blood Marrow Transplant; 1998; 4(3):142-50. PubMed ID: 9923412
[TBL] [Abstract][Full Text] [Related]
12. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
Baudo F; de Cataldo F
Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
[TBL] [Abstract][Full Text] [Related]
13. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
14. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
15. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.
Fourrier F; Chopin C; Goudemand J; Hendrycx S; Caron C; Rime A; Marey A; Lestavel P
Chest; 1992 Mar; 101(3):816-23. PubMed ID: 1531791
[TBL] [Abstract][Full Text] [Related]
16. Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.
Moubarak P; Zilker S; Wolf H; Hofner B; Kneib T; Küchenhoff H; Jauch KW; Hartl WH
Shock; 2008 Dec; 30(6):634-41. PubMed ID: 18520701
[TBL] [Abstract][Full Text] [Related]
17. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023].
Rublee D; Opal SM; Schramm W; Keinecke HO; Knaub S
Crit Care; 2002 Aug; 6(4):349-56. PubMed ID: 12225612
[TBL] [Abstract][Full Text] [Related]
18. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
[TBL] [Abstract][Full Text] [Related]
19. The use of antithrombin III (ATIII) for disseminated intravascular coagulation (DIC) during septic shock.
Cohendy R; Lefrant JY; de la Coussaye JE
Intensive Care Med; 1998 Dec; 24(12):1344. PubMed ID: 9885894
[No Abstract] [Full Text] [Related]
20. A prediction model of sepsis-associated acute kidney injury based on antithrombin III.
Xie Y; Zhang Y; Tian R; Jin W; Du J; Zhou Z; Wang R
Clin Exp Med; 2021 Feb; 21(1):89-100. PubMed ID: 32865720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
